Chugai Pharmaceutical Co. Ltd. is a rarity among Japanese companies, one that is pursuing a truly international corporate strategy. In conjunction with last week's announcement that the company was expanding its U.S. presence through the opening of a new biotechnology company in San Diego, Chugai Biopharmaceuticals Inc. (CBI), President Osamu Nagayama discussed Chugai's worldwide strategy with BioCentury.

As with other Japanese pharma companies, Chugai is facing profound changes in Japanese health care, as well as increasing competition and changes in health care in Europe and the U.S.